Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Get Free Report) COO Ross Moat sold 27,977 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $92.36, for a total transaction of $2,583,955.72. Following the completion of the transaction, the chief operating officer directly owned 10,294 shares in the company, valued at $950,753.84. This trade represents a 73.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ross Moat also recently made the following trade(s):
- On Friday, October 30th, Ross Moat sold 75,608 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $93.13, for a total transaction of $7,041,373.04.
Kiniksa Pharmaceuticals International Price Performance
NASDAQ:KNSA opened at $93.29 on Wednesday. Kiniksa Pharmaceuticals International, plc has a one year low of $37.02 and a one year high of $98.48. The company has a market cap of $7.28 billion, a PE ratio of 71.76 and a beta of 0.07. The firm has a 50-day moving average of $79.67 and a 200-day moving average of $60.56.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.19. The business had revenue of $285.97 million for the quarter, compared to analysts’ expectations of $260.66 million. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. On average, equities research analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current fiscal year.
Trending Headlines about Kiniksa Pharmaceuticals International
Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:
- Negative Sentiment: Across October 30 and November 2, CAO Michael Megna, COO Ross Moat, CFO Mark Ragosa and insider John Paolini reported sales totaling about 272,600 shares, worth approximately $25.4 million. The selling could weigh on sentiment or temper the stock’s recent momentum. However, each transaction was made under a pre-arranged Rule 10b5-1 plan, so it is not necessarily a response to new company developments. Megna SEC filing Moat SEC filing Paolini SEC filing Ragosa SEC filing
Institutional Trading of Kiniksa Pharmaceuticals International
A number of large investors have recently added to or reduced their stakes in KNSA. Ethic Inc. bought a new stake in Kiniksa Pharmaceuticals International in the third quarter worth about $726,000. Pictet Asset Management Holding SA boosted its stake in Kiniksa Pharmaceuticals International by 41.3% in the third quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock valued at $64,182,000 after acquiring an additional 251,578 shares during the last quarter. AlphaCentric Advisors LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the 3rd quarter valued at approximately $596,000. Commonwealth Equity Services LLC grew its position in shares of Kiniksa Pharmaceuticals International by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 10,871 shares of the company’s stock valued at $811,000 after acquiring an additional 237 shares during the period. Finally, Chicago Partners Investment Group LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the 3rd quarter valued at approximately $226,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on KNSA shares. Canaccord Genuity Group boosted their target price on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. The Goldman Sachs Group increased their price target on Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a research report on Wednesday, October 28th. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. Citigroup lifted their price target on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Finally, JPMorgan Chase & Co. boosted their price objective on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $100.57.
Read Our Latest Analysis on Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International Company Profile
Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.
Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.
The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.
Featured Stories
- Five stocks we like better than Kiniksa Pharmaceuticals International
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.
